PMID- 20384580
OWN - NLM
STAT- MEDLINE
DCOM- 20100913
LR  - 20220223
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
VI  - 10
IP  - 5
DP  - 2010 Aug
TI  - The mTOR pathway: a new target in cancer therapy.
PG  - 484-95
AB  - Mammalian target of rapamycin (mTOR) is a key protein kinase controlling signal 
      transduction from various growth factors and upstream proteins to the level of 
      mRNA translation and ribosome biogenesis, with pivotal regulatory effects on cell 
      cycle progression, cellular proliferation and growth, autophagy and angiogenesis. 
      The mTOR pathway, and its upstream regulators in the PI3K/PTEN/AKT cascade, are 
      altered in a variety of experimental and human malignancies.This has led to the 
      prediction that mTOR inhibitors may be used as anticancer agents. With the recent 
      approval of two mTOR-targeted drugs (temsirolimus and everolimus) for the 
      treatment of renal cell carcinoma and mantle cell lymphoma, this paradigm has 
      been effectively translated into the clinical setting. In this review, we discuss 
      mTOR biology and regulation, the mode of action of mTOR inhibitors as anti-cancer 
      agents, and current clinical evidence supporting the use of rapamycin-like mTOR 
      inhibitors in cancer treatment.
FAU - Ciuffreda, L
AU  - Ciuffreda L
AD  - Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio 
      Chianesi n. 53, 00144 Rome, Italy.
FAU - Di Sanza, C
AU  - Di Sanza C
FAU - Incani, U C
AU  - Incani UC
FAU - Milella, M
AU  - Milella M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*drug effects
MH  - Neoplasms/*drug therapy
MH  - Protein Serine-Threonine Kinases/*drug effects
MH  - TOR Serine-Threonine Kinases
RF  - 123
EDAT- 2010/04/14 06:00
MHDA- 2010/09/14 06:00
CRDT- 2010/04/14 06:00
PHST- 2009/12/14 00:00 [received]
PHST- 2010/03/29 00:00 [accepted]
PHST- 2010/04/14 06:00 [entrez]
PHST- 2010/04/14 06:00 [pubmed]
PHST- 2010/09/14 06:00 [medline]
AID - EPub-Abstract-CCDT-39 [pii]
AID - 10.2174/156800910791517172 [doi]
PST - ppublish
SO  - Curr Cancer Drug Targets. 2010 Aug;10(5):484-95. doi: 10.2174/156800910791517172.